REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers

BACKGROUND: Immune checkpoint inhibitors (ICI) have revolutionised treating advanced cancers. ICI are administered intravenously every 2–6 weeks for up to 2 years, until cancer progression/unacceptable toxicity. Physiological efficacy is observed at lower doses than those used as standard of care (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Merrick, Sophie, Nankivell, Matthew, Quartagno, Matteo, Clarke, Caroline S., Joharatnam-Hogan, Nalinie, Waddell, Tom, O'Carrigan, Brent, Seckl, Michael, Ghorani, Ehsan, Banks, Emma, Edmonds, Kim, Bray, George, Woodward, Rose, Bennett, Rachel, Badrock, Jonathan, Hudson, Will, Langley, Ruth E., Vasudev, Naveen, Pickering, Lisa, Gilbert, Duncan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614585/
https://www.ncbi.nlm.nih.gov/pubmed/36519749
http://dx.doi.org/10.1016/j.cct.2022.107030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614585/
https://www.ncbi.nlm.nih.gov/pubmed/36519749
http://dx.doi.org/10.1016/j.cct.2022.107030

Ejemplares similares